Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Nephrology

Background:

• Activation of the renin-angiotensin system (RAS) contributes to cardiovascular disease and target-organ damage, often exacerbated by hypertension.
• Dual RAS inhibition, specifically combining ACE inhibitors and ARBs, is a potential therapeutic strategy for enhanced blood pressure (BP) management and organ protection.

Purpose of the Study:

• To evaluate the potential benefits of combining ACE inhibitors and ARBs for managing hypertension and associated target-organ damage.
• To review existing evidence on dual RAS inhibition and identify limitations for definitive clinical conclusions.

Main Methods:

• Review of monotherapy studies with ACE inhibitors and ARBs, highlighting their effects on BP and RAS-related organ damage (nephropathy, congestive heart failure).
• Analysis of combination therapy studies, primarily involving ARB addition to ACE inhibitor regimens, in patients with heart failure and renal disease.
• Identification of limitations including study design, population variances, dosing strategies, and clinical endpoints that hinder definitive conclusions.

Main Results:

• Monotherapy with ACE inhibitors and ARBs shows comparable efficacy in BP control and reducing target-organ damage.
• Combination therapy has shown benefits in specific patient groups, such as those with congestive heart failure and renal disease.
• Variability across studies limits the ability to draw firm conclusions on the overall value of dual RAS inhibition.

Conclusions:

• While combination therapy with ACE inhibitors and ARBs shows promise, particularly in specific patient populations, definitive conclusions regarding its broad efficacy are pending.
• Ongoing clinical trials are designed to further elucidate the benefits and clinical utility of dual RAS inhibition.